P12.08 Immunocytokines are a novel immunotherapeutic approach against glioblastoma

ABSTRACT: Abstract

BACKGROUND

Glioblastoma is the most common malignant primary brain tumor in adults with an urgent need for novel treatment options. The administration of pro-inflammatory cytokines could be a potent immunotherapeutic approach to shift the balance between tumor-associated immunosuppression and immune activation. However, the systemic administration of therapeutically active doses of pro-inflammatory cytokines is not feasible due to toxic side effects and there is a need for strategies that enable a targeted delivery of pro-inflammatory cytokines to the tumor site.

METHODS

We investigated different antibody-cytokine fusion products that enable a targeted delivery of interleukin (IL)-2, IL-12 or tumor necrosis factor (TNF)-α to the tumor site by binding to a tumor-s

SUBMITTER: Weiss T 

PROVIDER: S-EPMC6796053 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature